Developer docs
API playgroundTry for free, no card

Search company profiles

Almac Discovery

Full company profile

uuid0004mzg

Namestring
Almac Discovery
Legal namestring
Almac Group
Websiteurl
almacgroup.com
Company typeenum
Private
Founded yearint
1970
Descriptiontext

Almac Discovery is the research-driven drug discovery subsidiary of Almac Group, a privately held pharmaceutical services organisation founded circa 1970 by Sir Allen McClay in Craigavon, Northern Ireland. The Discovery unit focuses on developing first-in-class preclinical-stage therapeutic assets, with ALM-401 — a first-in-class EGFRxROR1 bispecific antibody drug conjugate — representing its lead programme, which was out-licensed globally to Formosa Pharmaceuticals in May 2025. Almac Discovery is one of four core operating subsidiaries within Almac Group, alongside Almac Diagnostic Services (the group's precision medicine and CDx development arm), Almac Clinical Services/Technologies, Almac Pharma Services, and Almac Sciences. The broader Almac Group generated £1.1 billion in revenue in FY2024/25, up from over £1 billion the prior year, with a 16% profit increase, and operates 18 facilities across Europe, North America, and Asia with 7,900+ employees.

Almac's commercial platform spans the full drug development lifecycle, with revenue generated primarily through fee-for-service contracts with global biopharma clients. Core offerings include API and chemical development, pharmaceutical formulation, clinical trial supply and IXRS3 interactive response technology, commercial manufacturing, and an integrated diagnostic services business covering genomic services, clinical biomarker development, companion diagnostic (CDx) development and manufacturing, and global clinical trial testing. Diagnostic and biomarker operations are anchored in CLIA, CAP, and ISO15189-accredited laboratories in the UK (Craigavon) and US (Durham, NC), with additional capacity in Asia. Proprietary technology includes the claraT bioinformatics report (a Hallmarks of Cancer-based gene expression classifier), the DDIR/Angio/EMT/Prostate Dx/ColDx R&D assay portfolio, the PNPLA3 Genotyping Kit for MASH/MASLD research, the IXRS3 IRT platform, the Almac Trial Coordinator eClinical suite, and the Almac Gateway client portal. Almac claims involvement in approximately 50% of approved NMEs over the last six years and works with all top 25 global BioPharma companies.

The go-to-market model is direct enterprise sales with regional business development teams in the UK, US (Boston, Souderton, Durham), and Asia Pacific (Singapore, Tokyo, China partner lab), supported by scientific conference presence, thought-leadership content, and bespoke client data integrations. The Northern Ireland headquarters provides a distinctive post-Brexit regulatory position with access to both EU and UK markets under the Windsor Framework, including IVDR Article 5(5) Health Institution status. Strategic positioning combines a one-stop-shop integrated CDMO+diagnostics model with platform-agnostic flexibility (no exclusive vendor lock-in) and dedicated PhD-qualified project management per client programme, differentiating from both specialised CROs and large full-service CDMOs.

Short descriptiontext

Almac Discovery is the drug discovery arm of privately held Almac Group, developing first-in-class preclinical therapeutics and out-licensing programmes such as ALM-401. It operates within a broader integrated CDMO and precision medicine services platform serving top global biopharma clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersBelfast, United Kingdom
HQ citystring
Belfast
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, companion diagnostics development, biomarker assay services, clinical trial testing, pharmaceutical CDMO
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Drug Discovery and Pharmaceutical Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (Fee for Service)
TypeProfessional Services
Description

Almac operates as a fee-for-service Contract Development and Manufacturing Organisation (CDMO), providing services across the drug development lifecycle including API manufacture, formulation development, clinical trial supply, diagnostic services, and commercial-scale manufacturing. Revenue is generated through project-based contracts with biopharma clients.

almacgroup.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Project-specific fee for service model
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed - pricing varies by project scope, service type, and client requirements

almacgroup.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Almac Discovery is the drug discovery research arm of the Almac Group, developing first-in-class preclinical therapeutic assets such as ALM-401, a first-in-class EGFRxROR1 bispecific antibody drug conjugate out-licensed to Formosa Pharmaceuticals. Through affiliated operations, the broader group provides fee-for-service biomarker discovery, companion diagnostic (CDx) development, global clinical trial testing, genomic services, and contract development and manufacturing (CDMO) services for biopharma clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Revenue of £1.1 billion with 16% profit increase
+5 more records
Product overview1 text field

Almac Discovery is a research-driven drug discovery company dedicated to developing novel and innovative therapeutics using cutting-edge research techniques for First-in-Class preclinical stage assets. The broader Almac Group provides integrated pharmaceutical services across the drug development lifecycle. Almac Discovery's key product is ALM-401 (EGFRxROR1 bispecific ADC), licensed to Formosa Pharmaceuticals. The Diagnostic Services division offers genomic services, clinical biomarker & CDx development, and clinical testing. The company's technology platforms include claraT (gene expression reporting), LIMS (laboratory information management), Clinical Trial Dashboard, and Almac Gateway portal. Supporting services span API/chemical development, pharmaceutical development, analytical services, clinical services, clinical technologies (IXRS3, eCOA, eConsent), and commercial manufacturing services. The company operates CLIA/CAP/ISO15189 accredited global laboratories and holds multiple regulatory certifications including ISO13485, FDA, MHRA, and IVDR compliance.

Product and service27 records
1ALM-401
CategoryDrug Discovery - Therapeutic Asset
Description

First-in-class EGFRxROR1 bispecific antibody drug conjugate (ADC) developed by Almac Discovery and globally licensed to Formosa Pharmaceuticals for development and commercialisation as a novel oncology therapeutic.

2claraT Report
CategoryBioinformatics Software / Diagnostic Service
Description

Bioinformatics-driven gene expression classification solution that processes raw gene expression data and classifies biologically relevant gene expression signatures into comprehensive, easy-to-interpret reports using the Hallmarks of Cancer framework. Delivered with interactive dashboard functionality and 16 new gene expression signatures.

3Genomic Services
CategoryGenomic Services
Description

Range of genomic services including high-throughput DNA and RNA sequencing from multiple platforms, specialty central lab service, and data analysis solutions for biopharma clients.

4Clinical Biomarker and CDx Development
CategoryCompanion Diagnostics Development
Description

Custom clinical biomarker and companion diagnostics (CDx) development, validation and delivery from CLIA and CAP accredited laboratories in the USA, Europe and APAC.

5Global Clinical Trial Testing
CategoryClinical Trial Testing Services
Description

Global clinical trial testing service from clinical laboratories with a menu of platforms and assays and an integrated specimen collection and logistics service.

6Companion Diagnostics (CDx)
CategoryCompanion Diagnostics Development
Description

End-to-end companion diagnostic development including design control, assay development, validation, manufacturing (ssPMA and IVD kits), regulatory submissions and commercialisation support.

7CDx Manufacturing
CategoryCompanion Diagnostics Manufacturing
Description

Manufacturing of ssPMA lab developed tests and IVD kits with FDA engagement, process validation and CE-marking capabilities.

8Clinical Trial Specimen Collection and Logistics Service
CategoryClinical Trial Logistics Services
Description

End-to-end clinical trial specimen collection kit manufacturing, clinical trial material bulk kit supply and global logistics management across 150+ programmes and 500+ clinical sites.

9Specialty Central Lab Service
CategoryCentral Laboratory Services
Description

Premium white-glove specialty central lab service with end-to-end sample management, specimen processing, storage and downstream molecular analysis.

10Almac PNPLA3 Genotyping Kit
CategoryDiagnostic Kit / Genotyping Assay
Description

Qualitative PCR-based genotyping kit for identification of the I148M (rs738409) genotype within the PNPLA3 gene, used in MASH/MASLD liver disease research and clinical trials.

11PNPLA3/HSD17B13 Clinical Trial Assays
CategoryClinical Trial Assays
Description

qPCR genotyping clinical trial assays for PNPLA3 and HSD17B13 genes to determine molecular eligibility for MASH/MASLD clinical trials.

12DDIR (DNA Damage Immune Response) Assay
CategoryProprietary R&D Biomarker Assay
Description

Almac proprietary R&D assay for DNA damage immune response biomarker analysis, used to support clinical trial biomarker programmes.

13Angio Assay
CategoryProprietary R&D Biomarker Assay
Description

Almac proprietary R&D assay for angiogenesis biomarker analysis.

14EMT (Epithelial-Mesenchymal Transition) Assay
CategoryProprietary R&D Biomarker Assay
Description

Almac proprietary R&D assay for epithelial-mesenchymal transition biomarker analysis.

15Prostate Dx
CategoryProprietary R&D Diagnostic Assay
Description

Almac proprietary R&D diagnostic assay for prostate cancer.

16ColDx
CategoryProprietary R&D Diagnostic Assay
Description

Almac proprietary R&D diagnostic assay for colorectal cancer.

17WES MSI/TMB Scoring
CategoryGenomic Biomarker Assay
Description

Whole Exome Sequencing-based Microsatellite Instability and Tumor Mutational Burden scoring assays for oncology clinical trial programmes.

18API Services and Chemical Development
CategoryCDMO - API and Chemical Development
Description

Services for all stages of drug development for small molecules and peptides, including API manufacturing, 14C radiolabelling, biocatalysis, peptide synthesis and flow chemistry.

19Pharmaceutical Development
CategoryCDMO - Pharmaceutical Development
Description

Expert development and manufacturing solutions for all phases of clinical trials, including oral dose formulations and bioavailability enhancement.

20Analytical and Solid State Services
CategoryCDMO - Analytical Services
Description

Comprehensive solutions to support drug substance and drug product development including method development, release testing, stability testing and solid-state analysis.

21Clinical Services
CategoryClinical Trial Supply Services
Description

Comprehensive global clinical supply chain solutions including clinical trial supply, supply chain solutions, client services and patient-focused services.

22Clinical Technologies
CategoryClinical Trial Technology Solutions
Description

Clinical trial technology solutions including IXRS3 IRT, eCOA, eConsent, visit management and biostatistics consulting.

23Commercial Services
CategoryCDMO - Commercial Manufacturing and Distribution
Description

Commercial manufacturing, packaging, distribution and product launch services for solid oral dosage forms.

24Almac Gateway
CategoryClient Technology Platform
Description

Online portal providing access to multiple Almac services including My Dashboard, My Clinical Supplies, TempEZ, Label Approval System, Depot Network and Pharma POP.

25IXRS3 Interactive Response Technology
CategoryClinical Trial Technology / IRT
Description

Highly configurable Interactive Response Technology (IRT) platform for clinical trials with IRT Boosters including ART, OVERSIGHT and Decentralised Clinical Trial (DCT) support.

26Almac Trial Coordinator
CategoryClinical Trial Technology / eClinical Platform
Description

Integrated eClinical technology platform combining Interactive Response Technology (IRT), electronic Clinical Outcome Assessment (eCOA), electronic Consent (eConsent) and Visit Management into one unified system for clinical trials.

27Single Cell Sequencing Service
CategoryGenomic Services
Description

Single cell sequencing laboratory service offered by Almac Diagnostic Services to support biopharma research and clinical trial biomarker programmes.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-05-06
Description

Global licensing agreement for ALM-401, a first-in-class EGFRxROR1 bispecific antibody drug conjugate. Almac Discovery and Formosa Pharmaceuticals partnership covers global development and commercialisation of this novel therapeutic asset.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-04
Description

Key partnership for advancing biomarker research and precision medicine development in clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for tumour molecular profiling - establishing Almac Diagnostic Services as a reference laboratory for EORTC clinical studies, supporting standardised molecular profiling across European cancer clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing partnership for biomarker-driven clinical trials and companion diagnostic development across multiple therapeutic areas including chronic diseases.

5Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Precision medicine collaboration for clinical biomarker programmes.

almacgroup.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical biomarker and CDx development services for oncology and chronic disease programmes.

7Eisai
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genomic services partnership for clinical trial support.

almacgroup.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Oncology clinical trial biomarker and diagnostic services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial biomarker services for immuno-oncology programmes.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Companion diagnostic development for immunotherapy clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CDx development and validation for oncology drug candidate.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biomarker discovery and genomic analysis services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Companion diagnostic development partnership.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Biomarker programme collaboration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical trial assay development for AXL inhibitor programmes.

Strategic tierCoreTypeTechnology or Integration
Description

Platform partnership for TruSight Oncology 500 HRD and TruSight Oncology 500 ctDNA panel testing.

Strategic tierCoreTypeTechnology or Integration
Description

Platform partnership for Tumor Inflammation Signature (TIS), PAM50 Breast Cancer Subtyping, and Lymphoma Subtyping tests.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

IQVIA is the largest global CRO with extensive clinical lab, biomarker, and real-world data capabilities. It directly competes with Almac's CDMO and diagnostic services franchises, particularly in clinical trial testing and bioanalytical services.

TypeBroad incumbent
Description

Labcorp's Covance drug development arm combines central laboratory services with clinical research offerings, directly overlapping with Almac's clinical trial testing, biomarker, and CDx services for biopharma.

TypeBroad incumbent
Description

Charles River provides discovery, preclinical, and CDMO/biologics services. Its discovery and safety assessment businesses directly overlap with Almac Discovery's preclinical research and Almac Group's broader CRO/CDMO services.

TypeDirect peer
Description

ICON is a top-tier global CRO with significant biomarker and central lab capabilities post-PRA Health and Symphony integrations. It is a like-for-like CRO/CDMO competitor to Almac for biotech and biopharma clients.

TypeBroad incumbent
Description

Lonza is the world's largest CDMO with biologics, small molecule, and cell & gene therapy services. It directly competes with Almac's API manufacture, pharmaceutical development, and gene therapy support offerings.

TypeBroad incumbent
Description

Catalent provides drug development, delivery, and commercial manufacturing services, with strong biologics and cell therapy capabilities. It overlaps meaningfully with Almac's pharmaceutical development and clinical supply services.

TypeBroad incumbent
Description

Eurofins is a global testing services group with pharma services, genomic, and biomarker capabilities. It competes with Almac in clinical trial laboratory testing, genomic services, and biomarker assay development.

TypeBroad incumbent
Description

WuXi AppTec is a leading global CRO/CDMO with discovery, preclinical, and clinical services. Its discovery biology, bioanalytical, and biologics manufacturing capabilities make it a direct comparator to Almac Discovery and Almac Sciences.

TypeEmerging player
Description

Bio-Techne provides high-quality reagents, assays, and proteomic/genomic tools widely used in biomarker research. It overlaps with Almac's biomarker assay portfolio (e.g., DDIR, Angio, EMT) and serves a similar translational research customer base.

TypeEmerging player
Description

SOPHiA Genetics offers an AI-driven genomics platform for clinical and research applications, including homologous recombination deficiency (HRD) analysis. Almac is a validated platform partner, making SOPHiA a directly comparable bioinformatics/CDx peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance16 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Almac Discovery

Drug Discovery and Pharmaceutical Servicesalmacgroup.com

Almac Discovery is the drug discovery arm of privately held Almac Group, developing first-in-class preclinical therapeutics and out-licensing programmes such as ALM-401. It operates within a broader integrated CDMO and precision medicine services platform serving top global biopharma clients.

What Almac Discovery does

Almac Discovery is the research-driven drug discovery subsidiary of Almac Group, a privately held pharmaceutical services organisation founded circa 1970 by Sir Allen McClay in Craigavon, Northern Ireland. The Discovery unit focuses on developing first-in-class preclinical-stage therapeutic assets, with ALM-401 — a first-in-class EGFRxROR1 bispecific antibody drug conjugate — representing its lead programme, which was out-licensed globally to Formosa Pharmaceuticals in May 2025. Almac Discovery is one of four core operating subsidiaries within Almac Group, alongside Almac Diagnostic Services (the group's precision medicine and CDx development arm), Almac Clinical Services/Technologies, Almac Pharma Services, and Almac Sciences. The broader Almac Group generated £1.1 billion in revenue in FY2024/25, up from over £1 billion the prior year, with a 16% profit increase, and operates 18 facilities across Europe, North America, and Asia with 7,900+ employees.

Almac's commercial platform spans the full drug development lifecycle, with revenue generated primarily through fee-for-service contracts with global biopharma clients. Core offerings include API and chemical development, pharmaceutical formulation, clinical trial supply and IXRS3 interactive response technology, commercial manufacturing, and an integrated diagnostic services business covering genomic services, clinical biomarker development, companion diagnostic (CDx) development and manufacturing, and global clinical trial testing. Diagnostic and biomarker operations are anchored in CLIA, CAP, and ISO15189-accredited laboratories in the UK (Craigavon) and US (Durham, NC), with additional capacity in Asia. Proprietary technology includes the claraT bioinformatics report (a Hallmarks of Cancer-based gene expression classifier), the DDIR/Angio/EMT/Prostate Dx/ColDx R&D assay portfolio, the PNPLA3 Genotyping Kit for MASH/MASLD research, the IXRS3 IRT platform, the Almac Trial Coordinator eClinical suite, and the Almac Gateway client portal. Almac claims involvement in approximately 50% of approved NMEs over the last six years and works with all top 25 global BioPharma companies.

The go-to-market model is direct enterprise sales with regional business development teams in the UK, US (Boston, Souderton, Durham), and Asia Pacific (Singapore, Tokyo, China partner lab), supported by scientific conference presence, thought-leadership content, and bespoke client data integrations. The Northern Ireland headquarters provides a distinctive post-Brexit regulatory position with access to both EU and UK markets under the Windsor Framework, including IVDR Article 5(5) Health Institution status. Strategic positioning combines a one-stop-shop integrated CDMO+diagnostics model with platform-agnostic flexibility (no exclusive vendor lock-in) and dedicated PhD-qualified project management per client programme, differentiating from both specialised CROs and large full-service CDMOs.

Almac Discovery firmographics

Firmographics
Name
Almac Discovery
Legal name
Almac Group
Website
https://almacgroup.com
Company type
Private
Founded year
1970
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
Almac Discovery is the drug discovery arm of privately held Almac Group, developing first-in-class preclinical therapeutics and out-licensing programmes such as ALM-401. It operates within a broader integrated CDMO and precision medicine services platform serving top global biopharma clients.
Ownership category
akta.pro rank

Almac Discovery industry classification

Industry
Product category
Drug Discovery and Pharmaceutical Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAALAF
Companion Diagnostics (CDx) & Therapy Selection Assays
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Drug discovery services
  • Companion diagnostics development
  • Biomarker assay services
  • Clinical trial testing
  • Pharmaceutical CDMO

Where Almac Discovery is headquartered

Location

Headquarters

HQ city
Belfast
HQ country
United Kingdom
HQ region
Europe

Offices7 records

Markets served

Almac Discovery business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Research Services (Fee for Service): Almac operates as a fee-for-service Contract Development and Manufacturing Organisation (CDMO), providing services across the drug development lifecycle including API manufacture, formulation development, clinical trial supply, diagnostic services, and commercial-scale manufacturing. Revenue is generated through project-based contracts with biopharma clients.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-specific fee for service model

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Almac Discovery product offering

Product offering

Core offering

Almac Discovery is the drug discovery research arm of the Almac Group, developing first-in-class preclinical therapeutic assets such as ALM-401, a first-in-class EGFRxROR1 bispecific antibody drug conjugate out-licensed to Formosa Pharmaceuticals. Through affiliated operations, the broader group provides fee-for-service biomarker discovery, companion diagnostic (CDx) development, global clinical trial testing, genomic services, and contract development and manufacturing (CDMO) services for biopharma clients.

Product overview

Almac Discovery is a research-driven drug discovery company dedicated to developing novel and innovative therapeutics using cutting-edge research techniques for First-in-Class preclinical stage assets. The broader Almac Group provides integrated pharmaceutical services across the drug development lifecycle. Almac Discovery's key product is ALM-401 (EGFRxROR1 bispecific ADC), licensed to Formosa Pharmaceuticals. The Diagnostic Services division offers genomic services, clinical biomarker & CDx development, and clinical testing. The company's technology platforms include claraT (gene expression reporting), LIMS (laboratory information management), Clinical Trial Dashboard, and Almac Gateway portal. Supporting services span API/chemical development, pharmaceutical development, analytical services, clinical services, clinical technologies (IXRS3, eCOA, eConsent), and commercial manufacturing services. The company operates CLIA/CAP/ISO15189 accredited global laboratories and holds multiple regulatory certifications including ISO13485, FDA, MHRA, and IVDR compliance.

Differentiator

Problem solved

Functional benefit

Products and services

  • ALM-401 First-in-class EGFRxROR1 bispecific antibody drug conjugate (ADC) developed by Almac Discovery and globally licensed to Formosa Pharmaceuticals for development and commercialisation as a novel oncology therapeutic.
  • claraT Report Bioinformatics-driven gene expression classification solution that processes raw gene expression data and classifies biologically relevant gene expression signatures into comprehensive, easy-to-interpret reports using the Hallmarks of Cancer framework. Delivered with interactive dashboard functionality and 16 new gene expression signatures.
  • Genomic Services Range of genomic services including high-throughput DNA and RNA sequencing from multiple platforms, specialty central lab service, and data analysis solutions for biopharma clients.
  • Clinical Biomarker and CDx Development Custom clinical biomarker and companion diagnostics (CDx) development, validation and delivery from CLIA and CAP accredited laboratories in the USA, Europe and APAC.
  • Global Clinical Trial Testing Global clinical trial testing service from clinical laboratories with a menu of platforms and assays and an integrated specimen collection and logistics service.
  • Companion Diagnostics (CDx) End-to-end companion diagnostic development including design control, assay development, validation, manufacturing (ssPMA and IVD kits), regulatory submissions and commercialisation support.
  • CDx Manufacturing Manufacturing of ssPMA lab developed tests and IVD kits with FDA engagement, process validation and CE-marking capabilities.
  • Clinical Trial Specimen Collection and Logistics Service End-to-end clinical trial specimen collection kit manufacturing, clinical trial material bulk kit supply and global logistics management across 150+ programmes and 500+ clinical sites.
  • Specialty Central Lab Service Premium white-glove specialty central lab service with end-to-end sample management, specimen processing, storage and downstream molecular analysis.
  • Almac PNPLA3 Genotyping Kit Qualitative PCR-based genotyping kit for identification of the I148M (rs738409) genotype within the PNPLA3 gene, used in MASH/MASLD liver disease research and clinical trials.
  • PNPLA3/HSD17B13 Clinical Trial Assays qPCR genotyping clinical trial assays for PNPLA3 and HSD17B13 genes to determine molecular eligibility for MASH/MASLD clinical trials.
  • DDIR (DNA Damage Immune Response) Assay Almac proprietary R&D assay for DNA damage immune response biomarker analysis, used to support clinical trial biomarker programmes.
  • Angio Assay Almac proprietary R&D assay for angiogenesis biomarker analysis.
  • EMT (Epithelial-Mesenchymal Transition) Assay Almac proprietary R&D assay for epithelial-mesenchymal transition biomarker analysis.
  • Prostate Dx Almac proprietary R&D diagnostic assay for prostate cancer.
  • ColDx Almac proprietary R&D diagnostic assay for colorectal cancer.
  • WES MSI/TMB Scoring Whole Exome Sequencing-based Microsatellite Instability and Tumor Mutational Burden scoring assays for oncology clinical trial programmes.
  • API Services and Chemical Development Services for all stages of drug development for small molecules and peptides, including API manufacturing, 14C radiolabelling, biocatalysis, peptide synthesis and flow chemistry.
  • Pharmaceutical Development Expert development and manufacturing solutions for all phases of clinical trials, including oral dose formulations and bioavailability enhancement.
  • Analytical and Solid State Services Comprehensive solutions to support drug substance and drug product development including method development, release testing, stability testing and solid-state analysis.
  • Clinical Services Comprehensive global clinical supply chain solutions including clinical trial supply, supply chain solutions, client services and patient-focused services.
  • Clinical Technologies Clinical trial technology solutions including IXRS3 IRT, eCOA, eConsent, visit management and biostatistics consulting.
  • Commercial Services Commercial manufacturing, packaging, distribution and product launch services for solid oral dosage forms.
  • Almac Gateway Online portal providing access to multiple Almac services including My Dashboard, My Clinical Supplies, TempEZ, Label Approval System, Depot Network and Pharma POP.
  • IXRS3 Interactive Response Technology Highly configurable Interactive Response Technology (IRT) platform for clinical trials with IRT Boosters including ART, OVERSIGHT and Decentralised Clinical Trial (DCT) support.
  • Almac Trial Coordinator Integrated eClinical technology platform combining Interactive Response Technology (IRT), electronic Clinical Outcome Assessment (eCOA), electronic Consent (eConsent) and Visit Management into one unified system for clinical trials.
  • Single Cell Sequencing Service Single cell sequencing laboratory service offered by Almac Diagnostic Services to support biopharma research and clinical trial biomarker programmes.

Quantifiable outcome

  • Revenue of £1.1 billion with 16% profit increase
  • +5 more outcomes

Companies that use Almac Discovery

Customer profile

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Almac Discovery technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability5 records

Feature9 records

Almac Discovery partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered flagship, core and minor.

  • Formosa PharmaceuticalsflagshipStrategic or Co-development Partner · 6 May 2025Global licensing agreement for ALM-401, a first-in-class EGFRxROR1 bispecific antibody drug conjugate. Almac Discovery and Formosa Pharmaceuticals partnership covers global development and commercialisation of this novel therapeutic asset.
  • Future Medicines InstitutecoreStrategic or Co-development Partner · 4 December 2024Key partnership for advancing biomarker research and precision medicine development in clinical trials.
  • EORTC (European Organisation for Research and Treatment of Cancer)coreStrategic or Co-development PartnerCollaboration for tumour molecular profiling - establishing Almac Diagnostic Services as a reference laboratory for EORTC clinical studies, supporting standardised molecular profiling across European cancer clinical trials.
  • AstraZenecacoreStrategic or Co-development PartnerLong-standing partnership for biomarker-driven clinical trials and companion diagnostic development across multiple therapeutic areas including chronic diseases.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerPrecision medicine collaboration for clinical biomarker programmes.
  • JanssencoreStrategic or Co-development PartnerClinical biomarker and CDx development services for oncology and chronic disease programmes.
  • EisaicoreStrategic or Co-development PartnerGenomic services partnership for clinical trial support.
  • Chiesi (Turning Point)coreStrategic or Co-development PartnerOncology clinical trial biomarker and diagnostic services.
  • Corvus PharmaceuticalsminorStrategic or Co-development PartnerClinical trial biomarker services for immuno-oncology programmes.
  • OSE ImmunotherapeuticsminorStrategic or Co-development PartnerCompanion diagnostic development for immunotherapy clinical trials.
  • Puma BiotechnologycoreStrategic or Co-development PartnerCDx development and validation for oncology drug candidate.
  • NucanaminorStrategic or Co-development PartnerBiomarker discovery and genomic analysis services.
  • PredictImmuneminorStrategic or Co-development PartnerCompanion diagnostic development partnership.
  • CellCentricminorStrategic or Co-development PartnerBiomarker programme collaboration.
  • BerGenBiominorStrategic or Co-development PartnerClinical trial assay development for AXL inhibitor programmes.
  • IlluminacoreTechnology or IntegrationPlatform partnership for TruSight Oncology 500 HRD and TruSight Oncology 500 ctDNA panel testing.
  • nanoStringcoreTechnology or IntegrationPlatform partnership for Tumor Inflammation Signature (TIS), PAM50 Breast Cancer Subtyping, and Lymphoma Subtyping tests.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Almac Discovery competitors and assessment

Company assessment

Broad incumbents

  • IQVIA: IQVIA is the largest global CRO with extensive clinical lab, biomarker, and real-world data capabilities. It directly competes with Almac's CDMO and diagnostic services franchises, particularly in clinical trial testing and bioanalytical services.
  • Labcorp (Covance): Labcorp's Covance drug development arm combines central laboratory services with clinical research offerings, directly overlapping with Almac's clinical trial testing, biomarker, and CDx services for biopharma.
  • Charles River Laboratories: Charles River provides discovery, preclinical, and CDMO/biologics services. Its discovery and safety assessment businesses directly overlap with Almac Discovery's preclinical research and Almac Group's broader CRO/CDMO services.
  • Lonza Group: Lonza is the world's largest CDMO with biologics, small molecule, and cell & gene therapy services. It directly competes with Almac's API manufacture, pharmaceutical development, and gene therapy support offerings.
  • Catalent: Catalent provides drug development, delivery, and commercial manufacturing services, with strong biologics and cell therapy capabilities. It overlaps meaningfully with Almac's pharmaceutical development and clinical supply services.
  • Eurofins Scientific: Eurofins is a global testing services group with pharma services, genomic, and biomarker capabilities. It competes with Almac in clinical trial laboratory testing, genomic services, and biomarker assay development.
  • WuXi AppTec: WuXi AppTec is a leading global CRO/CDMO with discovery, preclinical, and clinical services. Its discovery biology, bioanalytical, and biologics manufacturing capabilities make it a direct comparator to Almac Discovery and Almac Sciences.

Direct peers

  • ICON plc: ICON is a top-tier global CRO with significant biomarker and central lab capabilities post-PRA Health and Symphony integrations. It is a like-for-like CRO/CDMO competitor to Almac for biotech and biopharma clients.

Emerging players

  • Bio-Techne: Bio-Techne provides high-quality reagents, assays, and proteomic/genomic tools widely used in biomarker research. It overlaps with Almac's biomarker assay portfolio (e.g., DDIR, Angio, EMT) and serves a similar translational research customer base.
  • SOPHiA Genetics: SOPHiA Genetics offers an AI-driven genomics platform for clinical and research applications, including homologous recombination deficiency (HRD) analysis. Almac is a validated platform partner, making SOPHiA a directly comparable bioinformatics/CDx peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Almac Discovery social profiles

Digital presence

Almac Discovery compliance and trust

Trust signal

Compliance16 records

Almac Discovery financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Almac Discovery leadership team

Management profile

Number of profiles

Profiles1 record

Almac Discovery subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Almac Discovery funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Almac Discovery M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almac Discovery

What does Almac Discovery do?

Almac Discovery is the drug discovery research arm of the Almac Group, developing first-in-class preclinical therapeutic assets such as ALM-401, a first-in-class EGFRxROR1 bispecific antibody drug conjugate out-licensed to Formosa Pharmaceuticals. Through affiliated operations, the broader group provides fee-for-service biomarker discovery, companion diagnostic (CDx) development, global clinical trial testing, genomic services, and contract development and manufacturing (CDMO) services for biopharma clients.

Is Almac Discovery a public or private company?

Almac Discovery is a private company. It is classified as family owned and is currently operating.

When was Almac Discovery founded?

Almac Discovery was founded in 1970. It employs 5,001 to 10,000 people.

Where is Almac Discovery based?

Almac Discovery is headquartered in Belfast, United Kingdom, in the Europe region.

How does Almac Discovery make money?

One revenue line is on record: contract Research Services (Fee for Service).

Who are Almac Discovery's main competitors?

Broad incumbents on record are IQVIA, Labcorp (Covance), Charles River Laboratories, Lonza Group, Catalent, Eurofins Scientific and WuXi AppTec. ICON plc is listed as a direct peer. Emerging players are Bio-Techne and SOPHiA Genetics.

Does Almac Discovery have an API?

No public API is recorded for Almac Discovery.

What industry is Almac Discovery in?

Almac Discovery's product category is Drug Discovery and Pharmaceutical Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Irish TimesRCSI’s precision medicine master’s graduates are ready for the next evolutionRCSI University of Medicine and Health Sciences is graduating students from its Master’s programme in technologies and analytics in precision medicine (MScTAPM) to address a critical skills gap in biological data science. The programme, developed with input from industry partner Almac Diagnostic Services, aims to equip graduates with the ability to analyse healthcare data using AI and genomics to improve patient outcomes. This initiative responds to projected growth in the precision medicine market, which is expected to reach $138.67 billion by 2026.BioWorldAlmac Discovery presents data on USP19 inhibitor for cancer-induced cachexiaAlmac Discovery presented data on a USP19 inhibitor for cancer-induced cachexia. About 80% of advanced cancer patients are affected by cachexia, a metabolic wasting syndrome characterized by weight loss.PR NewswireAlmac Discovery and HitGen Announce Strategic Research CollaborationAlmac Discovery and HitGen announced a research collaboration to identify novel compounds against selected deubiquitinating enzyme (DUB) targets. HitGen will screen its library of over 1.2 trillion small molecules against Almac's targets, with initial hits validated and advanced into research and development programmes.PR NewswireElasmogen Announces Grants Of 2 New VNAR and soloMER Patent FamiliesElasmogen Ltd announced that two new patent families for its VNAR and soloMER biologics platforms have been granted in multiple territories including the US, Europe, Canada, Japan, China, and Australia. These intellectual property rights secure the company's drug-discovery platform and support ongoing commercial partnerships, such as the collaboration with Almac Discovery Ltd focused on cancer treatments.Scotland NewsDrug discovery firm returns to work with grant funding to combat Covid-19Elasmogen, a drug discovery firm from the University of Aberdeen, secured £143,000 from the Scottish Government and £204,000 from UKRI to resume research after lockdown barred scientists from labs. The grants enabled the firm to restart work on its cancer drug conjugates and a joint project with Almac Discovery.PR NewswireAlmac Discovery to Present Updates on Key Oncology Programmes at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting IIAlmac Discovery announced it will present new data on two lead oncology programs at the 2020 AACR Virtual Annual Meeting II, being held June 22-24. The programs include a next-generation protein drug conjugate (ADP-c165) targeting ROR1, which demonstrated complete and durable regressions in patient-derived xenograft models, and a small molecule inhibitor program targeting USP7 that revealed a novel mechanism for reprogramming the tumor microenvironment. Both programs are advancing toward the nomination of candidate drugs, with the company highlighting significant progress over the past year.PR NewswireAlmac Discovery et Debiopharm International SA annoncent un accord de licence pour le développement d'un nouvel inhibiteur de Wee-1Almac Discovery and Debiopharm International SA announced a licensing agreement to develop Wee-1 kinase inhibitors. Debiopharm received exclusive worldwide rights to Almac's Wee-1 patent families, with upfront and milestone payments plus royalties. The companies aim to advance these compounds for cancer treatment.PR NewswireAlmac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 InhibitorAlmac Discovery and Debiopharm International SA announced a licensing agreement for Debiopharm to develop Almac's Wee-1 kinase inhibitor program. Debiopharm received exclusive global rights, with Almac eligible for an upfront payment, development and commercial milestones, and royalties. The companies aim to pursue the compound's development for cancer treatment.outsourcing-pharma.comCancer-hunting shark proteins are the future of drug conjugation, says AlmacAlmac and Elasmogen are collaborating on shark-derived vNAR proteins for drug conjugation, with the molecules being one-twelfth the size of human antibodies. The partnership targets an unnamed immuno-oncology target, with a preclinical candidate expected within two years. Almac holds an option on all commercialisation revenue.